Scrip Asks…What Does 2021 Hold For Biopharma? Part 3: Patient Access To Health Care

Level The Playing Field, Say Pharma Executives

Executives share their expectations and hopes around the multi-faceted topic of patient access to medicines. From health inequities to value assessment and reimbursement trends, expectations for change abound.

Scrip Asks, Part 3, Medical
• Source: Shutterstock

SCRIP ASKS…What Does 2021 Hold For Biopharma?

A broad survey of the industry's expectations for the year to come.

Every December, Scrip asks industry leaders and experts to share their expectations for the year to come. With responses from more than 200 professionals, Scrip Asks…What Does 2021 Hold For Biopharma? provides an unprecedented insight into the biopharma universe's collective crystal ball.

The full list of installments:

"COVID-19 is a great reminder and a testament that biopharma's core mission is to meet patient and society's needs." These words of Lihua Yu, president and chief data science officer of Eisai Co., Ltd

This third installment of our Scrip Asks… annual forecast series is therefore dedicated to perspectives that could be loosely grouped under

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D